ROOT, Switzerland - Novocure (NASDAQ: NVCR) has announced successful results from its phase 3 METIS clinical trial, revealing that its Tumor Treating Fields (TTFields) therapy, combined with supportive care, significantly prolongs the time to intracranial progression in patients with brain metastases from non-small cell lung cancer (NSCLC). The trial showed a median time to intracranial progression of 21.9 months for patients receiving TTFields therapy versus 11.3 months for those receiving supportive care alone.
The study enrolled 298 adult patients who were treated with TTFields and supportive care following stereotactic radiosurgery (SRS). The primary endpoint, median time to intracranial progression, was met with a hazard ratio of 0.67 and a P-value of 0.016. TTFields therapy was reported to be well-tolerated, with a median treatment duration of 16 weeks and average usage of 67%. Quality of life and neurocognitive function were maintained throughout the treatment.
While the key secondary endpoints, including time to neurocognitive failure, overall survival, and radiological response rate, did not reach statistical significance, some showed positive trends favoring TTFields therapy, such as time to distant progression and quality of life. Full analysis of secondary endpoints is ongoing.
Minesh Mehta, MD, Chief of Radiation Oncology at Miami Cancer Institute, highlighted the significance of the trial's findings, suggesting the potential for TTFields therapy to change clinical practice by delaying brain relapse and improving patients' quality of life.
Novocure's CEO, Asaf Danziger, expressed pride in the company's commitment to addressing unmet medical needs and the encouraging performance of TTFields in the METIS trial. He extended gratitude to the patients and investigators involved in the study for their contributions to advancing the treatment of brain metastases from NSCLC.
Novocure plans to submit these data to regulatory authorities and aims to publish the findings in a peer-reviewed scientific journal, as well as present them at an upcoming scientific congress. The information in this article is based on a press release statement.
InvestingPro Insights
Amidst the promising clinical trial results for Novocure (NASDAQ: NVCR), investors and stakeholders are closely examining the company's financial health and market performance. Novocure's Tumor Treating Fields (TTFields) therapy presents a potential paradigm shift in treating brain metastases from non-small cell lung cancer, and the financial metrics offer additional context for evaluating the company's prospects.
One standout feature in Novocure's financial landscape is its impressive gross profit margin, which, as of the last twelve months ending in Q4 2023, stands at a robust 74.96%. This high margin underscores the company's ability to manage production and operational costs effectively, which could be pivotal as it prepares for potential regulatory submissions and broader market adoption of TTFields therapy.
Despite the clinical success, Novocure's market capitalization reflects investor caution, with a valuation of $1.4 billion. This figure comes alongside a negative price-to-earnings (P/E) ratio of -6.17, indicating that the company has not been profitable over the past year. Additionally, the stock has experienced significant price volatility, with a year-to-date total return of -12.46% and a steep decline of -77.58% over the past year, possibly reflecting market uncertainty about the path to profitability and the adoption rate of TTFields therapy.
However, it's not all challenging news on the financial front. Novocure holds more cash than debt on its balance sheet, which could provide the company with the flexibility to navigate the commercialization process for its TTFields therapy without being overly constrained by financial obligations. Moreover, three analysts have revised their earnings upwards for the upcoming period, hinting at a potential shift in market sentiment as Novocure continues to advance its clinical programs.
For investors seeking to delve deeper into Novocure's financials and market performance, PRONEWS24 grants an additional 10% off a yearly or biyearly Pro and Pro+ subscription to InvestingPro. There, subscribers can access a comprehensive list of 11 additional InvestingPro Tips, which provide further insights into Novocure's financial health and stock performance. Visit https://www.investing.com/pro/NVCR to explore these tips and more.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.